No abstract available
Keywords:
Alemtuzumab; B cell depleting agents; Disease-modifying therapies; Multiple sclerosis; Neuromyelitis optica spectrum disorder; Ocrelizumab; Vaccines.
MeSH terms
-
Humans
-
Immunologic Factors / therapeutic use*
-
Immunotherapy*
-
Multiple Sclerosis / prevention & control*
-
Multiple Sclerosis / therapy*
-
Vaccines / therapeutic use*
Substances
-
Immunologic Factors
-
Vaccines